GJA1 and myeloid sarcoma: Numerous reports in a variety of models (e.g., SCI, stroke, MS) suggest that imatinib alters endothelial tight junction protein expression (e.g., claudin 5, occludin, e-cadherin, connexin 43, beta-catenin) and improves vascular integrity (Vrekoussis et al., 2006; Su et al., 2008; Ma et al., 2011; Abrams et al., 2012; Aman et al., 2012; Adzemovic et al., 2013; Chislock and Pendergast, 2013; Zhan et al., 2015; Langer et al., 2019; Wang et al., 2020).